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Abstract
Background: Multimodality treatment is widely performed for clinical T1N0M0 (UICC-TNM classification, 7th edition)
thoracic esophageal squamous cell carcinoma (ESCC), but available articles regarding treatment results are limited.
This study assessed the outcomes of clinical T1N0M0 thoracic ESCC invading the muscularis mucosa (MM) or submucosa
(SM) treated with radiotherapy (RT) or chemoradiotherapy (CRT).
Methods: We retrospectively reviewed the medical charts of 90 patients with clinical T1N0M0 thoracic ESCC treated
with RT or CRT in our hospital in 2004–2011. Of these 90 patients, we analyzed the cases of 71 patients who met our
inclusion criteria. All 71 patients had MM or SM cancer. In the 47 patients treated with CRT, the chemotherapy regimen
of 5-fluorouracil (5-FU) plus cisplatin (CDDP) was used for 46 patients and 5-FU and nedaplatin was used for one patient.
Forty-five patients underwent endoscopic resection (ER) followed by RT or CRT as an additional treatment. Elective nodal
irradiation (ENI) was used in 39 patients. For all analyses, statistical significance was defined as 0.05, and the Bonferroni
correction was used for the multivariate analysis.
Results: The median age was 70 years (range 47–84). With a median follow-up of 43.6 months (range 1.5–124.2), the
5-year overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS) rates were 64.0, 72.8 and 50.
0 %, respectively. The multivariate analysis showed that performance status (PS) was an independent prognostic factors
for DSS and DFS (DSS, p < 0.001; DFS, p < 0.001). Chemotherapy in addition to RT showed a trend for better DSS
(p = 0.032) but was not significant following Bonferroni correction. ER and ENI were not significant predictive
factors for DSS and DFS.
Conclusions: PS was an independent prognostic factor for DSS and DFS. ER and ENI had no significant relationship
with DSS or DFS. The present results may be helpful in treatment decisions for clinical T1N0M0 thoracic ESCC.
Keywords: T1N0M0, Superficial esophageal cancer, Depth of tumor invasion, Chemoradiotherapy, Radiotherapy,
Elective nodal irradiation, Endoscopic submucosal dissection, Endoscopic mucosal resection
Background
Several therapeutic options have been developed for
clinical T1N0M0 (UICC-TNM classification, 7th edition)
thoracic esophageal squamous cell carcinoma (ESCC):
surgery, radiotherapy (RT), chemoradiotherapy (CRT),
endoscopic resection (ER) including endoscopic mucosal
resection (EMR), and endoscopic submucosal dissection
(ESD). Radical surgery with regional lymph node dissec-
tion has been the mainstay of the treatment for clinical
T1N0M0 ESCC. Along with the development of endo-
scopic equipment, ER becomes widely used for treating
early-stage esophageal cancer [1, 2]. ER followed by RT
or CRT is also one of the treatment strategies for ESCC
cases with a higher risk of lymph node or distant metas-
tasis. A retrospective analysis suggested that the overall
survival (OS) of patients with superficial ESCC treated
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by CRT was comparable to that of patients treated with
radical surgery [3, 4]. Definitive CRT is another option
for ESCC patients who are not candidates for surgery. In
their analysis of 72 patients with T1N0M0 ESCC treated
by CRT, the Japan Clinical Oncology Group reported
that the four-year survival rate was 80.5 % and the four-
year major relapse-free survival rate was 68 % [5].
Although clinical T1N0M0 ESCC is categorized as a
superficial cancer, the depth of tumor invasion to the
mucosal or submucosal layer is closely related to the
survival and metastasis rates [6–8]. Based on their retro-
spective analysis of 402 ESCC patients treated with ER,
Yamashina et al. reported that the cumulative 5-year me-
tastasis rates of patients with epithelium/lamina propria
(EPM/LPM), muscularis mucosa (MM), and submucosa
(SM) cancer were 0.4, 8.7 and 25.7 %, respectively [8]. In
UICC-TNM classification (7th edition), T1a includes
EPM/LPM and MM cancers, and T1b includes SM can-
cers. The results of their multivariate analysis indicated
that survival and risk of metastasis were associated
mainly with invasion into the MM or SM. They con-
cluded that based on the rate of lymph node metastasis,
clinical T1N0M0 ESCC invading the MM or SM should
be distinguished from EP/LPM cancer.
In organ-conserving treatments for clinical T1N0M0
ESCC, the depth of tumor invasion is closely related to
the treatment approach. Additional treatments after ER
are essential in MM or SM cancer, due to their higher
rates of lymph node metastasis [9]. The indication for
additional treatments after ER is based not only on the
depth of tumor invasion, but also on pathological find-
ings including the resection margin, venous invasion and
lymphatic invasion. In organ-conserving treatments, al-
though some retrospective analyses showed that ER
followed by CRT was effective for patients with superfi-
cial ESCC [10, 11], the necessity of ER for MM or SM
cancer is not yet well understood. The goal of the
present study was to determine the prognostic and pre-
dictive factors in cases of clinical T1N0M0 thoracic




We retrospectively reviewed the medical charts of 90 pa-
tients with clinical T1N0M0 thoracic ESCC treated with
RT or CRT at our hospital between 2004 and 2011. At
our hospital, almost all clinical T1N0M0 thoracic ESCC
patients are advised to undergo surgery or ER due to its
favorable survival rate and safety. However, some pa-
tients were not fit for surgery because of complications,
their general condition, or age. Therefore, most of the
patients in the present series were ineligible for or de-
clined to undergo radical surgery. Of the 90 patients, we
identified 71 patients who met all of our inclusion cri-
teria: (1) younger than 85 years of age, (2) histologically
proven squamous cell carcinoma, (3) depth of tumor in-
vasion limited to the MM or SM, (4) no lymph node or
distant metastasis, (5) no history of esophageal cancer,
(6) no other primary cancers at the diagnosis of ESCC,
and (7) preserved organ function to undergo definitive
RT or CRT. Of the initial 90 patients, 19 patients were
excluded: nine patients with synchronous other primary
cancers, eight with EP/LPM esophageal cancer, one pa-
tient ≥85 years old, and one patient with esophageal
adenocarcinoma.
The length and circumferential spread of each tumor
was measured for 71 patients (100 %) by esophagogas-
troduodenoscopy (EGD). The depth of tumor invasion
was evaluated for 70 patients (98.6 %) by endoscopic
ultrasound (EUS), and the remaining one patients were
evaluated comprehensively. For the patients treated with
ER before RT or CRT, the depth of tumor invasion was
determined by pathological examination. Lymph node or
distant metastases were ruled out by EUS and computed
tomography (CT) for 71 patients (100 %), and positron
emission tomography/computed tomography (PET/CT)
for 56 patients (78.9 %). The Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) was evalu-
ated by physicians or nurses at the diagnosis. Written
informed consent was obtained from all patients before
each treatment. This retrospective study was approved
by the Keiyukai Sapporo Hospital Institutional Review
Board.
Endoscopic resection
Curative ER was performed in 45 patients before their
RT or CRT. Of these 45 patients, 42 received ESD and
the other three patients received EMR. The ER specimen
of each patient was examined pathologically for histo-
logical type, depth of tumor invasion, resection margin,
lymphatic and venous invasion of tumor.
Radiotherapy and chemoradiotherapy
RT planning was performed with a CT simulator and ra-
diation treatment planning system: Pinnacle ver. 8.0–9.6
(Philips, Eindhoven, The Netherlands). We defined the
regional lymph node area as the bilateral supraclavicular,
periesophageal, mediastinal and perigastric lymph node
areas. We defined the prophylactic RT that included
these lymph node areas as elective nodal irradiation
(ENI). For primary tumors that did not undergo ER, the
gross tumor volume (GTV) was contoured on the plan-
ning CT images according to all available resources. The
GTV was expanded to the clinical tumor volume (CTV)
by extending a 2–3-cm margin superiorly and inferiorly,
and a 0.5-cm margin laterally. In the ENI cases, the
CTV included all prophylactic regional lymph nodes
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together with the primary tumor or tumor bed. In the
non-ENI cases, the CTV included the primary tumor or
tumor bed with an optional part of the regional lymph
nodes. The planning target volume (PTV) was then cre-
ated by adding a 1–1.5-cm margin to the CTV.
The techniques of ENI were different during the pe-
riods when RT was performed. From July 2004 to March
2009, the dose of 39.6–48 Gy in 20–24 fractions was de-
livered to the isocenters with anterior/posterior opposed
portals. From April 2009 to 2011, the dose of 50.4 Gy in
28 fractions was delivered with anterior/posterior op-
posed and additional oblique portals [12]. In non-ENI,
the dose of 39.6–48 Gy in 20–24 fractions was delivered
with anterior/posterior opposed portals. After the initial
plan was completed, a tumor boost of 9–20 Gy was de-
livered with cord-sparing oblique portals to the primary
tumor or tumor bed after ER. All patients were treated
5 days a week.
The standard dose of chemotherapy was 5-fluorouracil
(5-FU) 700 mg/m2 on days 1–5 and cisplatin (CDDP)
70 mg/m2 on day 1. Two courses of 5-FU plus CDDP
(FP) were administered during radiotherapy at intervals
of at least 3 weeks depending on the hematological data
or the general condition of the patient. For one patient
with decreased renal function, nedaplatin (CDGP) was
used instead of CDDP. A reduced dose (75 % of the stand-
ard dose) was used for the patients who were ≥80 years
old and the patients with a limited daily activity level.
Follow-up
After their RT or CRT was completed, all patients were
included in the follow-up program. The EGD and CT
were performed every 4–6 months for the first 5 years.
After 2006, when a small lesion was observed on CT im-
ages at a periodic follow-up, PET-CT was also applied to
determine whether or not the small lesion was metastatic.
When suspected lesions were found by EGD, biopsies of
the esophagus were also performed. Lymph node or dis-
tant metastases were examined by CT or PET-CT. Lymph
node metastasis was recorded according to the Japanese
Society for Esophageal Diseases’ classification of esopha-
geal cancer, 10th edition [13]. The patients who had been
diagnosed with local recurrence or metastasis received
salvage treatment including ER, surgical operation, chemo-
therapy, RT, CRT or palliative treatment.
Statistical analysis
The follow-up started on the first day of radiotherapy
and ended as one of the following: date of death, date of
the patient’s last visit to our hospital, or date that the pa-
tient was last known to be alive confirmed by telephone
interview or a letter from the patient’s referring phys-
ician. We calculated the OS rate and the disease-specific
survival (DSS) rate from the start date of RT to the date
of the last follow-up. We calculated the disease-free
survival (DFS) rate from the start date of RT to the
earliest occurrence of recurrences or death. Residual
tumors after RT or CRT were counted as treatment
failure immediately.
Toxicities were scored according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE) version 4.0. We used the
Kaplan-Meier method to determine the survival rates,
with statistical significance assessed by the log-rank
test. We used Cox proportional hazards models to evalu-
ate potential associations between the clinical factors and
DSS or DFS. For all analyses, a two-sided p-value <0.05
was considered significant. For the multivariate analysis,
the Bonferroni correction was used and the significance
value of 0.05 was divided by the number of factors to ob-
tain an adjusted significance level. The statistical analyses
were conducted using SPSS software (version 23; IBM
SPSS statistics, Chicago, IL, USA).
Results
Patient characteristics and treatments
The patients’ characteristics are summarized in Table 1.
Of all 71 patients, 57 patients were PS 0, ten were PS 1
and four were PS 2 or worse. The reasons of three PS 3
cases were as follows: vertebral compression fracture,
lower body paralysis after a traffic accident and left hemi-
paralysis after a cerebral infarction. One patient was PS 2
because of old age. Of all 71 patients, 18 patients under-
went RT, eight were administered CRT, six underwent ER
followed by RT, and 39 underwent ER followed by CRT.
Of the 45 patients treated with ER, 42 patients underwent
ESD and three underwent EMR. Two patients were un-
able to finish the prescribed radiation course; RT of
one patient was stopped at the dose of 28 Gy due to
radiation pneumonitis, and the other patient’s RT was
stopped at the dose of 52 Gy for a private reason. In
the RT group, 20 of the 24 patients were treated with
a local RT field, whereas in the CRT group, 35 of the
47 patients were treated with ENI. Of the 47 patients
in the CRT group, 35 were treated with two cycles of
standard-dose FP, six patients were treated with two
cycles of low-dose FP, and the other six patients re-
ceived one cycle of FP or CDGP instead of CDDP.
Disease-specific survival
With a median follow-up of 43.6 months, the 5-year
OS and DSS rates of all 71 patients were 64.0 and
72.8 %, respectively. Of all cases, 15 patients died due
to their ESCC or a treatment-related event. Five patients
died due to the following (one patient each): suicide,
cerebral infarction, lymphoma, myocardial infarction,
and heart failure.
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Thus, to identify ESCC-related predictive and prognos-
tic factors, we used univariate and multivariate analyses
for DSS. In the univariate analysis, PS (=0), radiation dose
(≤50 Gy), ER, and CRT were significant predictive and
prognostic factors (Table 2). The multivariate analysis re-
vealed that PS and CRT were significant factors, with haz-
ard ratios (HRs) of 8.72 (95 % confidence interval [CI]:
2.76–27.59, p < 0.001) for PS and 0.29 (95%CI: 0.092–0.90,
p = 0.032) for CRT (Table 3). After adjustment with the
Bonferroni correction, PS was the only significant pre-
dictive factor. For the patients with PS 0 and those
with PS 1–3, the 5-year DSS rates were 78.8 and 53.8 %
(p < 0.001), respectively (Fig. 1a).
Disease-free survival and patterns of recurrences
Recurrences were observed in 23 patients, including nine
with local recurrence, nine with regional lymph node
metastasis, five with distant metastasis. After their re-
currences were found, seven patients underwent salvage
ER, nine received chemotherapy, three underwent sur-
gery and the remaining four patients received other
treatments. Of the 23 patients with recurrences, 13 had
undergone CRT for their primary ESCC (Table 4). In
these patients, lymph node metastases tend to be found
more often in the right neck or right upper mediasti-
num than other sites.
The 5-year DFS rate of all 71 patients was 50.0 %. The
univariate analysis for each clinical factor identified PS
(=0), radiation dose (≤50 Gy), ER, and CRT as predictive
factors for DFS (Table 3). The multivariate analysis
showed that PS was an independent prognostic factor
for DFS with the HR of 5.31 (95%CI: 2.40–11.78, p <
0.001). The 5-year local control rate was 86.6 %, and ER
was shown by the multivariate analysis to be a signifi-
cant predictive factor (Additional file 1: Table S1 and
Additional file 2: Table S2). In the patients with PS 0
and PS 1–3, the 5-year DFS rates were 60.7 and 0 %
(p < 0.001), respectively (Fig. 1b).
Late toxicity
Adverse late events (≥ grade3) were identified in five pa-
tients, all of whom had been administered CRT (Table 5).
Radiation pneumonitis developed in two patients. Of these
two patients, one patient had refused medical treatment
for radiation pneumonitis and died 20 days after CRT.
The 60-year-old patient with grade 5 toxicity had had
liver cirrhosis before CRT and died due to heart failure
at 43 months after CRT. The other grade 5 toxicity
case, a 76-year-old patient, had had hypertension and
died due to myocardial infarction at 45 months after
CRT.
Discussion
The present analysis of organ-conserving treatment for pa-
tients with clinical T1N0M0 thoracic ESCC demonstrated
that PS was an independent prognostic factor for both
DSS and DFS. ER was not a significant predictive factor in










≥ 1 14 19.7
Observation period (months)
Median 43.6 (range 1.5–124.2)
Main tumor location
Upper thoracic 12 16.9
Middle thoracic 41 57.7
Lower thoracic 18 25.4
Depth of tumor invasion
Muscularis mucosa 6 8.5
Submucosa 65 91.5
Tumor length (cm)
Median 4.0 (range 1–30)
Circumferential spread of tumor
Median 0.50 (range 0.17–1)
Tumor number
1 65 91.5




ER + RT (ESD/EMR) 6 (4/2) 8.5





Median 50.4 (range 28–68)
Chemotherapy
Standard dose FP (2 cycles) 35 74.5
Low-dose FP (2 cycles) 6 12.8
Others 6 12.8
CRT chemoradiotherapy, EMR endoscopic mucosal resection, ENI elective nodal
irradiation, ER endoscopic resection, ESD endoscopic submucosal dissection,
FP 5FU + Cisplatin, RT radiotherapy
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the multivariate analysis despite its significance in local
control. Although a few research groups suggested that
the combined treatment of ER followed by CRT was ef-
fective [10, 11], the role of ER in MM or SM esophageal
cancer is controversial. The present results may be helpful
for choosing the appropriate treatment and predicting the
prognosis for each patient.
Our multivariate analysis with Bonferroni correction re-
vealed that CRT was not an independent predictive factor
for DSS and DFS. For DSS, however, CRT showed a trend
for better survival (p = 0.032 without Bonferroni correc-
tion). Few articles reported significant effectiveness of
CRT compared to RT alone in superficial ESCC. Cooper et
al. reported that CRT resulted in increased OS rate
Table 2 Univariate analysis for disease-specific survival and disease-free survival rates
n 5-year DSS (%) p-value 5-year DFS (%) p-value
Age
≤ 70 37 77.8 0.574 55.4 0.117
> 70 34 65.7 44.3
Sex
Male 57 70.9 0.925 49..7 0.917
Female 14 76.2 51.9
Performance status
0 57 78.8 <0.001 60.7 <0.001
≥ 1 14 53.8 0
Main tumor location
Upper thoracic 12 0 0.205 64.8 0.186
Middle thoracic 41 80.1 57.2
Lower thoracic 18 74.9 25.5
RT field
Non-ENI 32 62.3 0.094 42.0 0.389
ENI 39 81.7 55.3
Radiation dose
≤ 50 Gy 32 88.5 0.003 61.6 0.035
> 50 Gy 39 55.0 38.0
Tumor length
≤ 5 cm 55 70.5 0.540 50.9 0.818
> 5 cm 16 85.2 50.6
Circumferential spread of tumor
≤ 0.75 63 71.2 0.464 47.7 0.302
> 0.75, ≤1 8 83.3 68.6
Tumor number
1 65 62.8 0.170 51.2 0.149
≥ 2 6 100 44.4
Depth of tumor invasion
Muscularis mucosa 6 100 0.227 26.7 0.808
Submucosa 65 70.7 51.3
Endoscopic resection
No 26 53.6 0.005 33.8 0.014
Yes 45 82.9 58.8
Chemotherapy
No 24 54.5 0.005 44.1 0.036
Yes 47 80.8 53.7
DSS disease-specific survival, DFS disease-free survival, ENI elective nodal irradiation, RT radiotherapy
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compared to RT alone, but their trial included locally ad-
vanced squamous cell carcinoma and adenocarcinoma
cases [14]. In their analysis of 464 surgically resected cases
after EMR, Eguchi et al. reported that ESCC invading the
MM or SM was a high-risk condition for lymph node
metastasis [9]. They proposed that MM or SM cancer
should be distinguished from EP or LPM cancer and
treated as a systemic disease due to their higher poten-
tial for metastasis.
In our present retrospective analysis of 71 patients
with MM or SM cancer, 47 patients were treated with
CRT. Of these 47 patients, 13 patients (27.7 %) were di-
agnosed with tumor recurrence. Lymph node or distant
metastasis was identified in 9 of these 13 patients during
the follow-up period. Despite the early clinical stage, the
ESCC invading the MM or SM cancer easily metasta-
sized. These patients might have had occult metastasis
at the time of diagnosis. Because ER is a local treatment
for MM or SM lesions, chemotherapy with RT may be
effective for eliminating these microscopic metastases. In
the present study, three patients with grade 5 toxicity
had undergone CRT. The death of one of these three pa-
tients, a 71-year-old patient with radiation pneumonitis,
was speculated to be directly associated with treatment
toxicity, although the patient had refused to undergo ne-
cessary treatments. For the other two patients with grade
5 toxicity, it is difficult to determine whether the CRT
was directly associated with their death considering
their ages and medical histories. However, there is no
doubt that CRT is a more invasive treatment than RT
alone. Therefore, the treatment indications of CRT
should be decided carefully depending on the patients’
backgrounds. The present results may be helpful in
making treatment decisions for clinical T1N0M0 thor-
acic ESCC.
Our multivariate analysis showed that PS was the only
independent prognostic factor for DSS and DFS. Our
study included 14 patients who were PS1–3 because they
were ineligible or refused to undergo radical surgery.
These patients’ backgrounds might have contributed to
the significance of PS. Previous studies have reported
Table 3 Multivariate analysis for disease-specific survival and
disease-free survival rates
Disease-specific survival Disease-free survival
Characteristics HR (95 % CI) p-value HR (95 % CI) p-value
Performance status
0 1 <0.001* 1 <0.001*
≥ 1 8.72 (2.76–27.59) 5.31 (2.40–11.78)
Radiation dose
≤ 50 Gy 1 1 0.618
> 50 Gy 2.15 (0.46–10.07) 0.331 1.31 (0.45–3.81)
Endoscopic resection
No 1 0.268 1 0.656
Yes 2.67 (0.47–15.20) 1.31 (0.40–4.30)
Chemotherapy
No 1 0.032 1 0.184
Yes 0.29 (0.092–0.90) 0.59 (0.27–1.29)
HR hazard ratio, CI confidential interval, ENI elective nodal irradiation,
RT radiotherapy. *Indicates significance after adjustment with Bonferroni
correction (p-value < 0.0125)
a
b
Fig. 1 Disease-specific survival a and disease-free survival b rates in
the PS 0 and PS 1–3 patients
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that PS was a prognostic factor for survival in patients
with stage I–IV esophageal cancer treated with RT or
CRT [15–17].
In MM or SM esophageal cancer treated with definitive
RT or CRT, the effectiveness of ER is still controversial.
According to the Japan Esophageal Society guidelines for
the treatment of esophageal cancer, the absolute indica-
tion for ER is EP or LPM cancer [18]. Lesions reaching
the MM or SM are defined as relative or investigational
indications because these cancers have a risk of lymph
node or distant metastasis. Shimizu et al. reported that ER
combined with CRT was favorable treatment for patients
with ESCC invading the MM or upper SM, because none
of 15 patients treated with ER followed by CRT had local
recurrence or metastasis [10]. However, the statistical
analysis in their article was insufficient because of the
small number of patients.
Based on their retrospective analysis of patients with
ESCC invading the MM or SM, Kawaguchi et al. also re-
ported that patients treated with ESD followed by CRT
had favorable OS compared to the patients treated with
CRT alone [11]. Although their paper described the ef-
fectiveness of ER followed by CRT for patients with
superficial ESCC, no significant difference was found in
the survival rate between patients treated with ER and
without ER. Because their study included superficial
ESCC patients with lymph node metastasis, the staging
variability in the enrolled patients might have affected
the treatment outcomes.
To investigate the role of ER in superficial ESCC
treated with RT or CRT, the accurate diagnosis of the
depth of tumor invasion is critical. In superficial ESCC
treated with ER, this treatment not only allows us to de-
termine the precise depth of tumor invasion; it is linked
to other prognostic factors such as the histological type,
the lymphatic and vascular involvement. In superficial
ESCC, EUS is considered to be most useful imaging
technique for evaluating the depth of tumor invasion,
and its diagnostic accuracy for mucosal and submucosal
cancers has been reported to be satisfactory [19, 20]. In
our present series of 71 patients, EUS was performed in
70 patients (98.6 %), and this high rate of EUS use sup-
ports its credible diagnosis of the depth of tumor invasion.
In our multivariate analysis for patients with clinical
T1N0M0 thoracic ESCC invading the MM or SM, ER
showed significance regarding the local control rate. How-
ever, ER was not shown to be an independent predictive
factor for DSS or DFS. ER is useful for local control and is
the definitive method to identify the depth of tumor inva-
sion; however, this result suggests that aggressive ER for
MM or SM cancers, which need additional treatment, is
not necessarily beneficial for survival.
ENI was not an independent predictive factor for DSS
or DFS in our study. Regarding the RT field, there is no
definitive consensus regarding whether or not ENI is
effective. Yamashita et al. retrospectively analyzed 126
patients with stage I–IV thoracic ESCC treated with
Table 4 Recurrences in patients treated with chemoradiotherapy
PS Location ER RT field Dose Recurrence site DFS Treatment for recurrence
0 Mt − ENI 60.0 Local 0 Surgery
1 Mt + ENI 28.0 Lung 6.1 Surgery
0 Ut − Non-ENI 40.0 Local 7.2 ESD
0 Mt + ENI 40.0 #104R 13.1 Chemotherapy
0 Lt + ENI 39.6 #3, #7 15.3 Surgery
0 Ut + ENI 50.4 #101R 19.8 Chemotherapy
0 Mt + ENI 40.0 #109R 22.5 Chemotherapy
0 Mt + ENI 39.6 #104R 28.5 Chemotherapy
0 Mt + ENI 65.0 #104R 30.7 Chemotherapy
0 Mt + Non-ENI 40.0 #104R 31.0 Chemotherapy
0 Mt + ENI 39.6 Local 43.2 ESD
1 Lt − Non-ENI 65.0 #106recR 58.3 Chemotherapy
0 Mt + ENI 40.0 Local 75.1 ESD
Lymph node metastasis was recorded according to the Japanese Society for Esophageal Diseases classification of esophageal cancer, 10th edition. #104:
supraclavicular LNs (lymph nodes), #3: LNs along the lesser curvature, #7: LNs along the left gastric artery, #101: cervical paraesophageal LNs, #109: main bronchus
LNs, #106rec: recurrent nerve LNs. DFS disease-free survival (months), Dose radiotherapy dose (Gy), ER endoscopic resection, ESD endoscopic submucosal dissection,
Lt lower thoracic esophagus, Mt middle thoracic esophagus, PS Performance status, RT field radiotherapy field, Ut upper thoracic esophagus
Table 5 Late toxicities in the 71 patients
Adverse events Grade 3 or 4 Grade 5
Radiation pneumonitis 1 1
Pleural effusion 1 0
Myocardial infarction 0 1
Heart failure 0 1
Toxicities were scored according to the NCI-CTCAE ver. 4.0
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CRT, and they concluded that ENI was effective for pre-
venting regional lymph nodal failure, because no patient
experienced elective nodal failure without having any
other site of recurrence [21]. In their analysis of 102 stage
I–IV ESCC patients treated with CRT, Onozawa et al. also
reported that ENI was effective for preventing regional
nodal failure, because only one patient (1.0 %; 95 %CI,
0–5.3 %) experienced elective nodal failure without any
other site of recurrence after achieving complete remis-
sion [22]. In contrast, Zhao et al. analyzed 53 patients
with T1N0–T4N1 ESCC without distant metastases treated
with RT, and they concluded that the omission of ENI was
not associated with a significant amount of failure in lymph
node regions [23]. One of the challenges in these studies is
that they included ESCC cases at various stages. Moreover,
chemotherapy may have contributed to the prevention
of lymph node metastasis in the previous studies. As
our research shows, ENI may not necessarily be required
for early ESCC.
A limitation of our study is that it was a non-
randomized and retrospective analysis of a single institu-
tion’s data. The treatment strategies for each patient also
differed somewhat over time. Some of the strengths of
our study include the relatively large number of patients,
accurate staging using PET-CT or EUS, and the long
follow-up period. To identify predictive and prognostic
factors in clinical T1N0M0 ESCC, a prospective ran-
domized controlled study of a large number of patients
is required.
Conclusion
The results of this study showed that PS was an inde-
pendent prognostic factor for both DSS and DFS in
patients with clinical T1N0M0 thoracic ESCC invading
the MM or SM. CRT showed a trend for better DSS
(p = 0.032) but was not significant after Bonferroni correc-
tion. ER and ENI were not identified as significant predict-
ive factors.
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